At a Glance
Andreessen Horowitz Bio + Health represents a16z's dedicated investment arm in biotechnology and digital health, launched to capitalize on the convergence of computation, engineering, and biology. The fund was established under the leadership of partners including Vineeta Agarwala and Jorge Conde, who brought deep scientific and medical expertise to complement a16z's technology investment platform. The Bio + Health fund focuses on companies that leverage computational approaches to solve healthcare's most pressing challenges, from drug discovery and diagnostics to care delivery and patient engagement. Notable investments include Freenome's liquid biopsy platform for early cancer detection, Devoted Health's Medicare Advantage platform, and Sana Biotechnology's engineered cell therapies. What distinguishes this fund is its ability to combine a16z's operational support infrastructure with specialized life sciences expertise, helping portfolio companies navigate regulatory pathways, clinical development, and healthcare market dynamics. The team includes former founders, physicians, and scientists who understand both the technical complexity and market realities of healthcare innovation.
“Backs founders using engineering-driven approaches to transform biology and healthcare, from computational drug discovery to clinical AI.”
Andreessen Horowitz Bio + Health primarily invests at the Seed, Series A, Series B+ stages. This means they focus on companies that are building their initial product and finding product-market fit.
Andreessen Horowitz Bio + Health is headquartered in Menlo Park, CA. Many of their portfolio companies are also based in this region, though they invest across geographies.
Andreessen Horowitz Bio + Health focuses on investments in Biotech, Digital Health, AI. Their portfolio reflects deep expertise and networks within these sectors.
Andreessen Horowitz Bio + Health's typical investment check size ranges from $2M to $100M. Actual amounts may vary based on the stage, sector, and specific opportunity.
Andreessen Horowitz Bio + Health manages approximately $3B in assets under management (AUM) across their funds.